DYRK1B expression is increased in quiescent cells and inhibition of DYRK1B can sensitize quiescent pancreatic and ovarian carcinoma cell lines to DNA damaging agents18, 19 and quiescent GIST cells to imatinib.11 This evidence concerns the gene DYRK1B and ovarian carcinoma.